| Literature DB >> 26472814 |
Ikuo Murakami1, Ran Zhang2, Masayuki Kubo2, Kenjiro Nagaoka2, Eri Eguchi2, Keiki Ogino3.
Abstract
Allergic asthma caused by continuous allergen exposure evokes allergen-specific Th2 responses and is characterized by chronic airway inflammation and hyperresponsiveness. A previous report showed that rebamipide improved asthmatic symptoms in an ovalbumin/trypsin mice model. However, it is still unclear how rebamipide exerts its effects in asthma. In this study, rebamipide improved the asthmatic responses induced by mite exposure in NC/Nga mice, revealing the mechanism of this therapeutic effect. Rebamipide suppressed the infiltration of eosinophils into the airways and lung as well as attenuating the production of reactive oxygen species in tissues. In addition to these anti-inflammatory effects, rebamipide inhibited the production of IL-33, a member of the IL-1 family that drives the subsequent production of Th2-associated cytokines. These observations identify the point where rebamipide exerts its suppressive action on asthma and suggest that rebamipide has therapeutic potential in preventing mite-induced asthma.Entities:
Keywords: IL-33; asthma; eosinophil; reactive oxygen species; rebamipide
Mesh:
Substances:
Year: 2015 PMID: 26472814 DOI: 10.1152/ajplung.00194.2015
Source DB: PubMed Journal: Am J Physiol Lung Cell Mol Physiol ISSN: 1040-0605 Impact factor: 5.464